Bioventus INC

Bioventus Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Bioventus Inc. reiterates its 2026 financial guidance following the FDA's reclassification of non-invasive bone growth stimulators, expecting minimal impact from updated CMS reimbursement rates.

Bioventus Inc. announced a robust first quarter for 2026, with revenue up 7% and significant improvements in profitability and cash flow, leading to raised full-year guidance.

Bioventus Inc. announced robust fourth quarter and full-year 2025 financial results, driven by organic revenue growth and improved profitability, alongside optimistic 2026 guidance.

Bioventus Inc. announced the appointment of Ajay Dhankhar, PhD, Chief Corporate Development & Strategy Officer of Smith & Nephew plc, to its Board of Directors, effective November 14, 2025.

Bioventus Inc. reported third-quarter 2025 financial results with reported revenue comparable to last year at $138.7 million, while organic revenue grew 8%, and GAAP earnings per diluted share increased to $0.05 from a prior-year loss.

Bioventus Inc. announced its first quarter 2026 financial results, showing a significant increase in net sales and a return to profitability.

Bioventus Inc. reported a significant return to profitability in Q3 2025, driven by reduced expenses and strategic product launches, despite a slight dip in net sales.

Bioventus Inc. reported a significant return to net income in Q2 2025, driven by strategic divestitures and new product clearances, despite a slight decline in overall net sales.

Bioventus Inc.'s Q1 2025 net sales decreased by 4.3% year-over-year, primarily due to the divestiture of its Advanced Rehabilitation Business.

Bioventus Inc. announced its third quarter 2024 financial results, including a net loss, and the planned divestiture of its Advanced Rehabilitation Business.

Bioventus Inc. announced its second quarter 2024 results, highlighting revenue growth alongside a significant impairment charge related to a planned divestiture and costs associated with a shareholder litigation settlement.

Bioventus Inc. reported a significant return to net income and increased Adjusted EBITDA in 2025, driven by strategic divestitures and new product launches, despite a slight dip in overall net sales.

Bioventus Inc. details its financial performance for the year ended December 31, 2024, highlighting net sales, net loss, and strategic business developments in its annual report.

Bioventus Inc. released its 2023 annual report, highlighting financial performance and strategic developments across its pain treatment, surgical solutions, and restorative therapies segments.

Director John Bartholdson exercised restricted stock units and received a new grant of equity in Bioventus Inc.

Director Martin Sutter acquired 32,282 shares of Bioventus Class A Common Stock via RSU vesting and was granted 25,146 new RSUs.

Director Susan Stalnecker acquired 32,282 shares of Bioventus Class A Common Stock via RSU vesting and was granted 25,146 new RSUs.

Director Guy Nohra acquired 32,282 shares of Bioventus Class A Common Stock through RSU vesting and was granted 25,146 new RSUs.

Director Guido Neels acquired 32,282 shares of Bioventus Class A common stock through RSU vesting and was granted 25,146 new RSUs.

Director Michelle McMurry-Heath acquired 32,282 shares of Bioventus Class A common stock via RSU vesting and received a new grant of 25,146 RSUs.

Bioventus Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 3, 2026, to elect directors and ratify the appointment of its independent auditor.

Bioventus Inc. has filed a definitive proxy statement with the SEC.

Bioventus Inc. will hold its annual stockholder meeting virtually on June 3, 2025, to vote on the election of directors and the ratification of its independent accounting firm.

Bioventus Inc. has engaged Morrow Sodali LLC to solicit proxies for its upcoming Annual Meeting of Stockholders to be held on June 11, 2024.

Bioventus Inc. has filed a definitive proxy statement with the SEC.

Bioventus Inc. is seeking stockholder approval for a charter amendment to declassify its Board of Directors and elect directors at the upcoming Annual Meeting on June 11, 2024.

BlackRock, Inc. has reported a beneficial ownership of 5.02% of Bioventus Inc.'s Class A Stock as of June 30, 2026.

Nantahala Capital Management and its managing members have reported a 9.03% beneficial ownership stake in Bioventus Inc. Class A Common Stock as of December 31, 2025.

Nantahala Capital Management and its managing members, Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 7.96% of Bioventus Inc.'s Class A Common Stock.